医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cogstate iPad Cognitive Assessments Selected for Use in Phase IV Observational Study of Approved Treatments for Prostate Cancer

2015年11月18日 PM10:00
このエントリーをはてなブックマークに追加


 

NEW HAVEN, Conn.

Cogstate Ltd (ASX:CGS), leaders in the measurement of cognition in clinical trials, is pleased to announce that their iPad-based computerized cognitive assessment technology has been selected for use in a multicenter Phase IV observational study to assess the tolerability of two approved drugs for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Supporting the growing interest in assessing neurotoxicity in oncology clinical trials, Cogstate’s computerized cognitive testing software provides rapid, sensitive measurements of distinct cognitive function, using novel stimuli designed for repeated administration by non-expert clinical staff. Tablet technologies have been thought to offer many benefits in clinical trials for their ease of use, portability and processing and display performance. Extensive usability and validation testing completed to date by Cogstate and independent researchers have confirmed that the Cogstate assessments provide equivalent results for completion and integrity when delivered on PC and tablet.

The Cogstate technology has been successfully deployed on iPads in a number of National Institutes of Health (NIH) funded studies, including the landmark public-private partnership studies, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4) and Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).

“While Cogstate’s computerized cognitive assessments have been used in over 1,200 trials across academic and clinical research, this study is significant because it marks the first time the technology has been delivered on the iPad for an industry sponsored Phase IV observational study in oncology,” said Brad O’Connor, Cogstate Chief Executive. “The rapid and scalable nature of well validated computerized assessments and the operational benefits of tablet-based delivery make it an ideal fit for large late-phase trials seeking to longitudinally monitor a drug’s impact on cognition.”

About Cogstate

Cogstate is a pioneer in commercializing rapid, reliable and highly sensitive computerised cognitive tests and provides expert support for traditional neuropsychological assessments to drive higher quality outcome measures. Cogstate clients include the world’s leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships. With more than 100 employees and a global network of expert neuropsychologist consultants across 25 countries, the unique intersection of science, innovation and delivery is at the core of everything we do.

Further information is available at www.cogstate.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005374/en/

CONTACT

Cogstate Media Contacts:
Australia
Brad
O’Connor, +613 9664 1300
Cogstate Chief Executive Officer
boconnor@cogstate.com
USA
Lammert
Albers, +1 203-773-5010
Cogstate Chief Commercial Officer
lalbers@cogstate.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease